Search by keyword.
Linker design is a critical aspect of drug discovery and development, playing a pivotal role in the efficacy and specificity of complex molecular structures such as antibody-drug conjugates (ADCs), bioconjugates, and targeted therapeutics. The design of effective linkers can significantly impact the stability, bioavailability, and overall performance of these compounds.
At SpiroChem, we develop a new generation of linkers that could potentially improve the potency, stability, selectivity, and drug metabolism and pharmacokinetics (DMPK) of ADCs and offer new possibilities for patent protection. These linkers can be designed to be cleaved under local physiological conditions or cellular environments, ensuring the controlled release of the drug payload at the target site.
1. Antibody-drug conjugates (ADCs) and other hybrid-biologics - developing linkers for ADCs that improve potency, stability, selectivity, and DMPK.
2. PROTAC applications - designing SpiroChem-branded linkers that influence the distance and orientation between the recruited E3 ligase and the target protein.
3. Bioconjugates - creating bioconjugation strategies involving various functional groups and innovative carbohydrate chemistry techniques.
4. Oligonucleotides - developing lipid- and carbohydrate-based formulations for nucleic acids, enhancing stability and delivery
